News
CBIO
--
0.00%
--
Analysts Have Conflicting Sentiments on These Healthcare Companies: Catalyst Biosciences (CBIO), Zoetis (ZTS) and Bluebird Bio (BLUE)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Catalyst Biosciences (CBIO), Zoetis (ZTS) and Bluebird
SmarterAnalyst · 17h ago
10-Q: CATALYST BIOSCIENCES, INC.
(EDGAR Online via COMTEX) -- ITEM 2. Management's Discussion and Analysis of Financial Condition and Results of Operations Unless otherwise indicated, in...
Edgar Online - (EDG = 10Q, 10K) · 20h ago
Cigna (CI) to Post Q1 Earnings: Will It Deliver a Beat?
Zacks.com · 21h ago
Microbial Long Chain Dicarboxylic Acid Market Trends 2021 Analysis By Industry Statistics, Progression Status, Emerging Demands, Business Opportunity, Share and Forecast To 2027 Says Precision Reports
May 06, 2021 (The Expresswire) -- Global “Microbial Long Chain Dicarboxylic Acid Market” research report offers qualitative and quantitative insights in...
The Express Wire · 22h ago
Is a Surprise Coming for Catalyst Biosciences (CBIO) This Earnings Season?
Catalyst Biosciences (CBIO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Zacks · 1d ago
Catalyst Biosciences, Inc. (CBIO) Reports Q1 Loss, Tops Revenue Estimates
Catalyst Biosciences, Inc. (CBIO) delivered earnings and revenue surprises of -2.60% and 46.70%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 1d ago
Catalyst Biosciences EPS misses by $0.12, beats on revenue
Catalyst Biosciences (CBIO): Q1 GAAP EPS of -$0.79 misses by $0.12.Revenue of $1.47M (-91.0% Y/Y) beats by $0.97M.Cash, cash equivalents and short-term investments of $107.0MPress Release
Seekingalpha · 1d ago
BRIEF-Catalyst Biosciences Reports Q1 Loss Per Share Of $0.79
reuters.com · 1d ago
Catalyst Biosciences Reports First Quarter 2021 Operating & Financial Results and Provides a Corporate Update
SOUTH SAN FRANCISCO, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced its operating and financial results for the first quarter ended March 31, 2021 and provided a corporate update. “We made significant pro...
GlobeNewswire · 1d ago
What's in Store for Select Medical (SEM) Earnings in Q1?
Zacks.com · 1d ago
8-K: CATALYST BIOSCIENCES, INC.
(EDGAR Online via COMTEX) -- false 0001124105 0001124105 2021-05-05 2021-05-05 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 1d ago
BRIEF-Catalyst Biosciences Announces First Patient Dosed In Phase 3 Study Of SQ MarzAA
reuters.com · 2d ago
Catalyst Biosciences Announces First Patient Dosed in Pivotal Phase 3 Registration Study of SQ MarzAA in Individuals with Hemophilia A or B with Inhibitors
SOUTH SAN FRANCISCO, Calif., May 05, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced the dosing of the first patient in the Crimson 1 Study, the Company's Phase 3 registration trial (MAA-304 - Crimson 1) of Marzeptacog al...
GlobeNewswire · 2d ago
Catalyst Biosciences Doses First Patient in Phase 3 Study of Potential Hemophilia Drug Candidate
MT Newswires · 2d ago
Global Factor Viii Deficiency Treatment Market Size 2021 with a CAGR of 5.59%, Research by Business Opportunities, Top Companies data report covers are Bayer HealthCare, CSL, Grifols
Apr 29, 2021 (The Expresswire) -- In 2021, “ Factor Viii Deficiency Treatment Market “ Size, Status and Market Insights, About Factor VIII Factor VIII is an...
The Express Wire · 04/29 05:55
Haemophilia Market 2021 to 2026 - Top Manufacturers, Business Strategy and Forecast Report
Apr 27, 2021 (AmericaNewsHour) -- Kenneth Research recently added a report on 'Haemophilia Market ' in its database of market research reports which provides...
AmericaNewsHour · 04/27 07:21
2 Strong Buy Penny Stocks That Could Deliver Massive Returns
TipRanks · 04/21 16:43
Haemophilia Treatment Market Size, Share, Growth,Trends, COVID-19 Analysis and Forecast 2021-2028
pune, India, Tue, 20 Apr 2021 22:59:06 / Comserve Inc. / -- The global Haemophilia Treatment market is thoroughly, accurately, and comprehensively assessed...
Comserve · 04/21 03:01
JonesTrading Thinks Catalyst Biosciences’ Stock is Going to Recover
In a report released today, Lina Kaminski from JonesTrading maintained a Buy rating on Catalyst Biosciences (CBIO), with a price target of $25.00. The
SmarterAnalyst · 04/19 17:45
Webull provides a variety of real-time CBIO stock news. You can receive the latest news about Catalyst Biosciences through multiple platforms. This information may help you make smarter investment decisions.
About CBIO
Catalyst Biosciences, Inc., formerly Targacept, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on creating and developing medicines to address serious medical conditions. The Company focuses its product development efforts in the fields of hemostasis, including the treatment of hemophilia and surgical bleeding, and inflammation, including prevention of delayed graft function (DGF) in renal transplants and the treatment of dry age-related macular degeneration (dry AMD), a condition that can cause visual impairment or blindness. The Company's advanced program is a coagulation Factor VIIa variant, CB 813d, that has completed a Phase I clinical trial in severe hemophilia A and B patients. In addition to its lead Factor VIIa program, it has approximately two other coagulation factors, a Factor IX variant, CB 2679d/ISU 304, that is in advanced preclinical development, and a Factor Xa variant that has reached the advanced lead preclinical-stage of development.